公开(公告)号：EP2542256A2

公开(公告)日：2013-01-09

申请号：EP11751204.6

申请日：2011-03-01

申请人： MacroGenics, Inc.

发明人： LOO, Deryk, T. ,  HUANG, Ling ,  CHEN, Francine Zhifen ,  MOORE, Paul A. ,  JOHNSON, Leslie S.

IPC分类号： A61K39/00 ,  C07K16/00

CPC分类号： C07K16/30 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2896 ,  C07K16/3076 ,  C07K16/3092 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/6893

摘要： The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

公开(公告)号：EP2029173A2

公开(公告)日：2009-03-04

申请号：EP07812341.1

申请日：2007-06-26

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling ,  GERENA, Robyn

IPC分类号： A61K39/395 ,  C07K16/00

CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

公开(公告)号：EP1761563A2

公开(公告)日：2007-03-14

申请号：EP05745396.1

申请日：2005-05-10

申请人： MACROGENICS, INC.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling

IPC分类号： C07K16/00 ,  C07H21/04 ,  A61K39/395 ,  C12N15/00 ,  C12N15/63

CPC分类号： C07K16/283 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34

摘要： The present invention relates to humanized FcϜRIIB antibodies, fragments, and variants thereof that bind human FcϜRIIB with a greater affinity than said antibody binds FcϜRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcϜRIIB.

公开(公告)号：EP3954703A2

公开(公告)日：2022-02-16

申请号：EP21185550.7

申请日：2015-05-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie S. ,  HUANG, Ling ,  CHICHILI, Gurunadh Reddy ,  SHAH, Kalpana ,  LAM, Chia-Ying, Kao ,  BURKE, Stephen, James ,  LIU, Liqin ,  MOORE, Paul, A. ,  BONVINI, Ezio ,  BARAT, Bhaswati

IPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61P1/04 ,  A61P1/16 ,  A61P5/00 ,  A61P9/10 ,  A61P11/00 ,  A61P13/10 ,  A61P13/12 ,  A61P17/00 ,  A61P19/00 ,  A61P21/00 ,  A61P35/02 ,  A61P35/00 ,  A61P35/04 ,  A61P1/18 ,  A61P13/00 ,  A61P13/08 ,  A61P15/00 ,  A61P25/00

摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

公开(公告)号：EP3808776A1

公开(公告)日：2021-04-21

申请号：EP20206324.4

申请日：2014-08-20

申请人： MacroGenics, Inc.

发明人： BONVINI, Ezio ,  JOHNSON, Leslie S. ,  MOORE, Paul A. ,  CHICHILI, Gurunadh Reddy ,  ALDERSON, Ralph Froman ,  HUANG, Ling

IPC分类号： C07K16/28 ,  C07K16/32 ,  A61K39/395 ,  A61K39/00 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/00 ,  A61P37/08 ,  A61P17/02

摘要： The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

公开(公告)号：EP2158221B1

公开(公告)日：2018-08-29

申请号：EP08771050.5

申请日：2008-06-13

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling

IPC分类号： C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  A61K39/00 ,  C07K16/46

CPC分类号： C07K16/468 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/283 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/62 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/92

摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non- peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody- like functionality to engineered into the molecule.

公开(公告)号：EP2601216B1

公开(公告)日：2018-01-03

申请号：EP11815113.3

申请日：2011-07-29

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling ,  RAINEY, Godfrey Jonah Anderson

IPC分类号： C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  C07K16/44 ,  C07K19/00

CPC分类号： A61K39/39558 ,  A61K38/164 ,  C07K14/315 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2851 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31 ,  C07K2319/70

摘要： Diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The diabody molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The diabody molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.

公开(公告)号：EP2714079B1

公开(公告)日：2016-09-14

申请号：EP12789439.2

申请日：2012-05-16

申请人： MacroGenics, Inc.

发明人： BONVINI, Ezio ,  BARAT, Bhaswati ,  HUANG, Ling ,  JOHNSON, Leslie S.

IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/32 ,  C07K16/44

CPC分类号： C07K16/32 ,  A61P35/00 ,  C07K14/315 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2851 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/62 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2319/31 ,  C07K2319/32 ,  C07K2319/73

摘要： The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules.

公开(公告)号：EP2247304B1

公开(公告)日：2016-05-25

申请号：EP09727180.3

申请日：2009-03-25

申请人： MacroGenics, Inc.

发明人： JOHNSON, Leslie, S. ,  HUANG, Ling ,  TUAILLON, Nadine ,  BONVINI, Ezio

IPC分类号： A61K39/395 ,  A61K45/06 ,  C07K16/32 ,  A61K39/00

CPC分类号： C07K16/32 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/92

公开(公告)号：EP2714733A2

公开(公告)日：2014-04-09

申请号：EP12790075.1

申请日：2012-05-16

申请人： MacroGenics, Inc.

发明人： HUANG, Ling ,  JOHNSON, Leslie, S.

IPC分类号： C07K16/00

CPC分类号： C07K16/2809 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/92

摘要： The present invention relates to CD3 -binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.

摘要翻译： 本发明涉及能够结合人和非人CD3，特别是与非人哺乳动物（例如食蟹猴）的CD3交叉反应的这些分子的CD3结合分子。 本发明还涉及这种抗体和抗原结合片段在治疗癌症，自身免疫和/或炎性疾病和其他病症中的用途。